Post-finasteride syndrome
An. bras. dermatol
; An. bras. dermatol;95(3): 271-277, May-June 2020. tab
Article
em En
| LILACS, ColecionaSUS
| ID: biblio-1130879
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Disfunções Sexuais Fisiológicas
/
Finasterida
/
Inibidores de 5-alfa Redutase
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
An. bras. dermatol
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article